FDA Flexes New FDAAA Muscle With ESA Safety Labeling - And May Help Tone Up Amgen’s Franchise
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency uses new authority to mandate label changes by Amgen and J&J in areas where negotiations were unsuccessful.
You may also be interested in...
With New Power, New Problems: FDA Confronts Complications of Safety Labeling Change Authority
Drug safety labeling changes that cover large classes of drugs are one of the biggest headaches FDA faces, given its new authority in this area under the Food and Drug Amendments Act, which established a new section 505(o) of the Food, Drug and Cosmetic Act.
With New Power, New Problems: FDA Confronts Complications of Safety Labeling Change Authority
Drug safety labeling changes that cover large classes of drugs are one of the biggest headaches FDA faces, given its new authority in this area under the Food and Drug Amendments Act, which established a new section 505(o) of the Food, Drug and Cosmetic Act.
Acceleron’s GDF Therapies: Just Different Enough?
EPO-like, Avastin-like portfolio is designed for “enormous” indications, but piggy-back possibilities are too early to forecast.